Rein Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $37.03M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | – | $-0.25 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | $-0.27 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | $-0.45 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 15, 2024 | During market hours | – | $-1.54 | – |
Press releases
Announcements Rein Therapeutics filed with the SEC
September 2026 Copyright © 2026 Rein Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Other events · EX-99.1 to Form 8-K
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of
Other events · EX-99.1 to Form 8-K
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic
Other events · EX-99.1 to Form 8-K
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Aileron Therapeutics Reports First Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
Aileron Therapeutics Announces CEO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: future expectations, plans and prospects for the Company following the consummation of the merger transaction (the “Merger”) between
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K